Pfizer and BioNTech receive recommendation for marketing authorization of their LP.8.1-adapted COVID-19 vaccine by the EMA’s CHMP for individuals 6 months and older. The adaptation targets the LP.8.1 variant for the upcoming 2025-2026 season, based on ETF’s recommendation. Data shows improved immune response against SARS-CoV-2 lineages compared to previous vaccine formulations.

Read more at Nasdaq: Pfizer, BioNTech Receive Positive CHMP Opinion For LP.8.1-adapted COVID-19 Vaccine